Congenica Completes $50m Series C Funding Round to Advance Clinical Genomic Analysis Software and Data Platform
The round was co-led by Tencent and Legal & General and included other new investors Xeraya, Puhua Capital and IDO Investments.
- The round was co-led by Tencent and Legal & General and included other new investors Xeraya, Puhua Capital and IDO Investments.
- The global nature of this important financing round brings new strategic and geographic capabilities that will further advance Congenicas existing global footprint.
- Congenica is recognised as a leader in the genomic analysis of rare diseases and inherited cancer.
- Congenicas world-leading software enables rapid genomic data analysis at scale, performing 20x faster than industry averages and providing a 30% higher analytical yield, reducing genomic interpretation costs by up to 95%.